Bellerophon Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	2017 - 2013
Period Ending	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	2017 - 2013
Net Income	-9.25	-19.83	-17.76	-24.73	-13.27	2.81	Upgrade
Depreciation & Amortization	0.01	0.07	0.1	0.15	0.35	0.36	Upgrade
Loss (Gain) From Sale of Assets	-0.14	-	-	-	-	-	Upgrade
Stock-Based Compensation	0.58	0.79	1.13	1.63	2.15	2.96	Upgrade
Other Operating Activities	-0	-0	-0.6	0.63	-2.01	-24.88	Upgrade
Change in Accounts Payable	-3.57	0.83	-5.49	2.45	-0.41	0.49	Upgrade
Change in Other Net Operating Assets	0.04	0.39	-0.2	-0.02	0.25	2.76	Upgrade
Operating Cash Flow	-12.34	-17.77	-22.82	-19.88	-12.94	-15.5	Upgrade
Investment in Securities	-	-	-	-	-	3	Upgrade
Investing Cash Flow	0.14	-	-	-	-	3	Upgrade
Issuance of Common Stock	5.01	-	-	57.75	6.24	0.19	Upgrade
Repurchase of Common Stock	-0.04	-0.04	-	-	-0.07	-	Upgrade
Other Financing Activities	-	-	-	-0.19	-	-0.03	Upgrade
Financing Cash Flow	4.97	-0.04	-	57.57	6.17	0.17	Upgrade
Net Cash Flow	-7.23	-17.81	-22.82	37.68	-6.77	-12.33	Upgrade
Free Cash Flow	-12.34	-17.77	-22.82	-19.88	-12.94	-15.5	Upgrade
Free Cash Flow Per Share	-1.11	-1.86	-2.40	-2.55	-2.87	-3.57	Upgrade
Levered Free Cash Flow	-9.7	-12.16	-16.74	-12.01	-8.79	-10.64	Upgrade
Unlevered Free Cash Flow	-9.7	-12.16	-16.74	-11.85	-8.79	-10.64	Upgrade
Change in Net Working Capital	3.38	-0.98	5.63	-2.79	0.37	-3.47	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.